What's driving the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Growth? Prominent Players: Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.
Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189
Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Treatment Market are;
• Grifols S.A.
• CSL Limited
• Kamada Ltd.
• Takeda Pharmaceutical Company Limited
• Abeona Therapeutics Inc., and other players.
The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market
In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.
KEY PLAYERS COVERED
Some of the major companies that are present in the global alpha-1 antitrypsin deficiency treatment market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.
North America to Dominate the Global Market
Rising number of AATD cases in North America is fuelling the demand for AATD augmentation therapy in this region. This in turn has led to the growth of AATD augmentation therapy market in North America and is likely to favor growth of the market in this region through the forecast period. There have been significant improvements in AATD diagnostic techniques used in many parts of Asia Pacific. Furthermore, the emphasis on AATD by the government in Asia Pacific is likely to enable growth in the regional market in the forthcoming years. Despite North America’s dominance, Asia Pacific will emerge as the fastest growing region in the forecast period.
The growth in global alpha-1 antitrypsin deficiency treatment market is being driven by the emerging guideline for the treatment and diagnosis of alpha-1 antitrypsin deficiency treatment, potential pipeline products and rising awareness of alpha-1 antitrypsin deficiency. Furthermore, the rising prevalence of alpha-1 antitrypsin deficiency is expected to boost the global alpha-1 antitrypsin deficiency treatment market in the forecast period.
Get Customization@ https://www.fortunebusinessinsights.com/enquiry/customization/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189
New Biological Approval for Prolastin C to Enable Growth of Global Market
In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market.
As Grifols’ products are used by a huge percentage of the global population, its new product approval will have a direct impact on the global market. Backed by successful therapies and efficient products, Grifols has accounted for the highest share in the global market. Recent product approvals have favoured the company and accounting to this, Grifols is likely to emrge dominant in the forecast period as well.
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release What's driving the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Growth? Prominent Players: Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics. here
News-ID: 1777766 • Views: 139
More Releases from Fortune Business Insights Pvt. Ltd.
How Food Processing Equipment Market Will Dominate In Coming Years? Key Players: …
The global food processing equipment market size is anticipated to witness remarkable growth in the forecast period attributable to the expansion of the food and beverage industry in various parts of the world. Fortune Business Insights studies in details the various facts and figures of the progress of this market in their report titled, "Food Processing Equipment Market Size, Share & Industry Analysis, By Equipment Type (Pre-processing Equipment, and Processing
What's driving the Social TV Market Growth? Prominent Players: Samsung Electroni …
Recent breakthroughs in technology in terms of broadband-delivered programming on smart televisions and personal computers are boosting the global social television market, predicts Fortune Business Insights in their recent study. The study is titled," Social TELEVISION Market Size, Share and Global Trend by Deployment (Software & Services), By Application (Sports, News, Television Shows, Others) and Geography Forecast till 2026." For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/social-tv-market-100309 According to
How Coronary Stents Market Will Dominate In Coming Years? Key Players: Biotronik …
The Global "Coronary Stents" Market is prognosticated to witness rapid growth in the coming years. In a report, titled, "Coronary Stents Market Size, Share and Global Trend By Deployment (Self and Balloon-expandable), Stent Type (Drug Eluting Stent, Bioresorbable Stent, Bare Metal Stent, Covered Stent and Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Catheterization Labs) and Geography Forecast till 2025". Fortune Business Insights identifies various factors enabling growth in
Why the mHealth Apps Market is set to explode? Top Companies: Fitbit, Inc., Appl …
The global "mHealth apps" market size is projected to reach USD 57.57 billion by 2026. Driven by the increasing number of novel product launches, the market will witness an impressive growth rate in the coming years. According to a report published by Fortune Business Insights, titled "mHealth Apps Market Size, Share & Industry Analysis, By App Type (Disease & Treatment Management, Wellness Management, Others), By Application (Monitoring Services, Fitness Solutions,
More Releases for AATD
AATD Augmentation Therapy Market: Grifols, S.A., Kamada Ltd, Shire plc (Baxalta) …
The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market has been boosted by recent FDA approval for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy Market: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2025. The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market
Increasing use of immunoglobulin in therapeutic areas and prevalence of emphysem …
Plasma fractionation is a process of separating various components of plasma. It is used in prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is used in treating protein deficiency in healthcare applications. It is also used in the production of packaging material for industrial applications. The removal or inactivation of viruses and prions is a prime function of plasma fractionation. Get the Sample
Global Alpha-Antitrypsin Deficiency Market: High Prevalence of Respiratory Disea …
Market Research Hub (MRH) has introduced a new report to its research repository on alpha-antitrypsin deficiency. The report is titled, "Alpha-Antitrypsin Deficiency-Market Insight, Epidemiology and Market Forecast-2027." The global alpha-antitrypsin deficiency market is picking up footing from various factors such as upgrades the diagnostics of alpha-1 antitrypsin deficiency, enhancing financial situation in different rising economies, plentiful of chances in the improvement of new items, and high neglected request over the globe.
Global Plasma Fractionation Market is Expected to Get US$ 26 Billion by 2022
The Global Plasma Fractionation Market is segmented on the lines of its product, application, end user and regional. Based on product segmentation it covers albumin, immunoglobulin, coagulation factor concentrates, protease inhibitors, other plasma fractionation products. Based on application segmentation it covers neurology, immunology, hematology, haemato-oncology, pulmonology, rheumatology, critical care, others. Based on end user segmentation it covers hospitals and clinics, clinical research laboratories, academic institutes. The Global Plasma Fractionation Market
Alpha- Antitrypsin Deficiency (AATD) – Market Insights, Epidemiology and Marke …
DelveInsight’s ‘Alpha Antitrypsin Deficiency – Market Insights, Epidemiology, and Market Forecast-2023’ report provides an overview of the Alpha Antitrypsin Deficiency and global market size of the Alpha Antitrypsin Deficiency for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan. The Report provides a comprehensive review of the market trends, drivers, barriers, key company profiles including its business and product developments. Alpha Antitrypsin Deficiency is the
Global Blood Plasma Industry Key Trends, Size, Growth, Shares And Forecast Resea …
Researchmoz added Most up-to-date research on "Global Blood Plasma Market Report: 2016 Edition" to its huge collection of research reports. The raw material for blood plasma industry is the liquid that is a component of blood called blood plasma. Blood plasma makes up approximately 55% of the total blood volume. Blood plasma is pale yellow in color and consists of water, proteins and salt. Those proteins are used to produce medicinal